Bio

Chris Ehrlich has been part of InterWest's life sciences team since 2000, focusing on investments in novel therapeutic approaches. He currently serves on the boards of two publicly owned companies: BioMimetic Therapeutics (BMTI) and Transcept Pharmaceuticals (TSPT). He also serves on the boards of several private companies, including: Carbylan BioSurgery, Follica, Invuity, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals, Xenon Pharmaceuticals and CVRx. Prior to joining InterWest, Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting.He also sits on advisory boards for the Innovation and New Ventures Office at Northwestern University and the Peter Michael Foundation. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.